F-Prime Capital

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery, particularly in underserved populations that have been historically underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample-to-bioinformatics platform, utilizing advanced algorithms and innovative analyses to enhance genomic discovery. By identifying patients at risk for severe multi-inflammatory syndromes and infections, Galatea Bio aims to develop new tests, treatments, and cures that can significantly improve healthcare outcomes for diverse populations.

Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system. We unite biological insights with clinically meaningful solutions to build and catalyze a diversified portfolio of transformative medicines. Harnessing our rigorous scientific approach to identify the most promising therapies, we leverage our flexible transaction model to advance assets with validated mechanisms and efficiently move them through development to commercialization.

Genomics plc is focused on transforming healthcare through advanced genomic analysis. The company employs sophisticated methodologies to analyze large integrated datasets of genomic and phenotypic information, aiming to enhance understanding of human biology. By leveraging genetic inference technology, Genomics plc seeks to identify new drug targets for serious diseases and assess individual disease risk. Their analytical platform enables the exploration of genomic sequence data, providing valuable insights that support pharmaceutical companies in reducing risks associated with drug development. This approach not only aims to improve healthcare outcomes but also sets a standard for how organizations and patients can benefit from genomic data.

Shinobi Therapeutics specializes in the development of cell therapies that leverage hypoimmune CD8αβ iPS-T cells to interact with the immune system for the treatment of cancer and various genetic diseases. The company's innovative approach incorporates advanced immune evasion technology to enhance the effectiveness and accessibility of these therapies. By focusing on durable responses and the potential for redosing, Shinobi aims to reduce costs and improve patient outcomes in the healthcare sector.

T-Therapeutics is a biopharmaceutical company specializing in the development of engineered soluble biologics for oncological and immunological conditions. The company utilizes a proprietary T cell receptor (TCR) discovery platform, which is based on a highly humanized mouse model. This innovative approach allows T-Therapeutics to identify TCRs that target human antigens not obtainable from human samples. The TCRs bind specific pMHC targets on target cells, facilitating the recruitment of T cells to either attack cancer cells or modulate immune responses. By leveraging advanced techniques in mouse genome engineering, single cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance treatment options for patients suffering from chronic and infectious diseases while fostering a culture of creativity and collaboration within its operations.

K36 Therapeutics is engaged in the development of small molecule therapeutics aimed at treating cancer. The company focuses on translating epigenetic modulation of oncogenic pathways into effective therapies, utilizing technology to create orally bioavailable small molecules and selective inhibitors. This innovative approach enables healthcare professionals to enhance treatment options for cancer patients, addressing the complexities of oncogenic pathways and improving therapeutic outcomes.

Delivering cost effective biosimilars by developing disruptive technologies, advanced analytics and state-of-the-art manufacturing facility. Being the most desired Biotech company to work for by creating an unparalleled work culture. Broadening the footprint of their innovative technologies through strategic global alliances.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Elucidata Corporation, founded in 2015 and headquartered in New Delhi, India, specializes in accelerating drug discovery through its proprietary SaaS platform, Polly. This platform transforms drug discovery by delivering machine learning-ready biomedical molecular data, supported by a vast repository of over 230,000 multi-omic datasets, with more than 50,000 datasets added monthly. Polly curates this data semi-automatically, enabling data-driven drug discovery teams to integrate proprietary and public biomedical data for machine learning applications. By adhering to the FAIR guidelines, Polly's Data Lakes provide exclusive access to curated multi-omics data, facilitating faster identification of therapeutic assets with a higher likelihood of clinical success. The platform has proven instrumental in detecting validated drug targets across various fields, including immunology, oncology, and metabolomic disorders. Elucidata collaborates with leading organizations such as Pfizer, Agios Pharmaceuticals, and Genentech, as well as over 35 research partners from prominent biopharma companies and research institutions, enhancing decision-making processes in drug research and development.

Immuneel Therapeutics provides pioneering cell and gene therapies for cancer treatment. They develop CAR-T cell therapies from patients' blood cells by genetically modifying healthy immune cells to target malignant cells, giving cancer patients access to revolutionary cell-based immunotherapies.

Peptone Ltd is a London-based company that specializes in developing artificial intelligence solutions aimed at addressing protein development challenges within the biotechnology, biopharmaceutical, and life sciences sectors. Established in 2016, Peptone focuses on the discovery of novel therapeutics, particularly targeting intrinsically disordered proteins. The company offers a range of services, including antibody design and optimization, a comprehensive protein database, and automated thermos-stability engineering. Its proprietary platform, CassandraAI, facilitates in silico protein engineering, enhancing the efficiency of protein development processes. Peptone's advanced protein engineering system addresses complex tasks such as anomaly detection and risk assessment, enabling clients to identify optimal strategies for resolving potential failures. This capability allows users to select suitable commercial partners to produce high-quality molecules more rapidly and cost-effectively than traditional methods employed in the pharmaceutical industry.

Proof Diagnostics is a life sciences company focused on developing diagnostic tools and therapeutic applications. It specializes in creating rapid diagnostic tests, including those for detecting infectious diseases such as coronavirus. The company offers diagnostic kits that enable medical professionals to test patients efficiently, enhancing the ability to identify infections quickly. Additionally, Proof Diagnostics is working on a smart, portable system aimed at improving the detection of various infectious diseases, thereby contributing to advancements in public health and disease management.

K36 Therapeutics is engaged in the development of small molecule therapeutics aimed at treating cancer. The company focuses on translating epigenetic modulation of oncogenic pathways into effective therapies, utilizing technology to create orally bioavailable small molecules and selective inhibitors. This innovative approach enables healthcare professionals to enhance treatment options for cancer patients, addressing the complexities of oncogenic pathways and improving therapeutic outcomes.

AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery, particularly in underserved populations that have been historically underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample-to-bioinformatics platform, utilizing advanced algorithms and innovative analyses to enhance genomic discovery. By identifying patients at risk for severe multi-inflammatory syndromes and infections, Galatea Bio aims to develop new tests, treatments, and cures that can significantly improve healthcare outcomes for diverse populations.

Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, specializing in the development of innovative platforms for the analysis of liquid and tissue biopsies. Founded in 2009, the company focuses on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs), which are critical for advancing precision medicine in oncology and cardiovascular disease. RareCyte's AccuCyte system offers an open platform that allows for the unbiased discovery and isolation of these rare cells from whole blood. The company provides a comprehensive suite of products, including sample preparation systems, staining kits, automated microscopy instruments, and imaging systems, which are utilized in various applications such as liquid biopsies, single-cell retrieval, and multi-parameter tissue analysis. By equipping researchers and medical professionals with advanced tools, RareCyte aims to enhance clinical research and foster the development of targeted therapies.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its proprietary Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aiming to restore normal genetic function and address the underlying causes of various diseases. By targeting a broad spectrum of conditions with significant unmet medical needs, Prime Medicine seeks to revolutionize the field of genetic medicine through effective and efficient therapeutic solutions.

Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.

Genomics plc is focused on transforming healthcare through advanced genomic analysis. The company employs sophisticated methodologies to analyze large integrated datasets of genomic and phenotypic information, aiming to enhance understanding of human biology. By leveraging genetic inference technology, Genomics plc seeks to identify new drug targets for serious diseases and assess individual disease risk. Their analytical platform enables the exploration of genomic sequence data, providing valuable insights that support pharmaceutical companies in reducing risks associated with drug development. This approach not only aims to improve healthcare outcomes but also sets a standard for how organizations and patients can benefit from genomic data.

LakeShore Biopharma is a global, fully integrated medical company engaged in discovering, developing and commercializing innovative biotherapeutics for cancers and infectious diseases using our novel PIKA® immunomodulating technology. PIKA technology augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. Products in clinical development include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 hepatitis B vaccine and the PIKA rabies vaccine for accelerated protection against rabies infection.

Sana Biotechnology is a biotechnology company based in Seattle, Washington, with additional offices in South San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the company specializes in developing engineered cells as medicines to treat a variety of diseases. Sana Biotechnology focuses on reprogramming cells in the body and replacing damaged cells and tissues, leveraging recent scientific advancements to create new therapeutic options. The company's research spans multiple therapeutic areas with significant unmet needs, including oncology, diabetes, B-cell-mediated autoimmune disorders, and central nervous system conditions. Its pipeline includes various product candidates aimed at addressing these challenges through innovative cell engineering programs.

Verve Therapeutics, Inc. is a genetic medicines company focused on innovative treatments for cardiovascular disease through gene editing. Founded in 2018 and based in Cambridge, Massachusetts, with a research facility in Philadelphia, the company aims to shift the management of cardiovascular conditions from chronic treatments to single-course gene editing therapies. Its initial programs concentrate on the PCSK9 and ANGPTL3 genes, which are known to significantly impact blood lipid levels, a major factor in cardiovascular disease. Verve Therapeutics collaborates with partners such as Beam Therapeutics and Verily to enhance its gene editing delivery technologies. The company is staffed by a team of experts in cardiovascular medicine, human genetics, and drug development, positioning itself to address the challenges of cardiovascular health effectively.

NFlection Therapeutics, Inc. is a biotechnology company dedicated to the discovery and development of targeted therapies for rare disorders. Based in Wayne, Pennsylvania, the company primarily addresses conditions such as neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks like keratinocytic epidermal nevi and nevus sebaceous. NFlection specializes in treatments that target the Ras/Raf/MEK/ERK signaling pathway, which is often aberrantly activated in these disorders. One of its notable developments includes a soft mitogen-activated protein kinase (MEK) formulated as a cosmetically elegant gel for topical application, allowing for localized treatment while minimizing systemic side effects typically associated with orally administered MEK inhibitors. Founded in 2014, NFlection Therapeutics aims to improve patient outcomes through innovative therapeutic solutions.

Rallybio is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with severe and rare disorders. Founded in 2018 and based in New Haven, Connecticut, the company is advancing its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a serious condition that can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's portfolio includes a range of promising product candidates targeting rare diseases across various therapeutic areas, including hematology, immuno-inflammation, maternal-fetal health, and metabolic disorders. The company's efforts are supported by a team of experienced professionals with extensive expertise in biopharma research and development.

Affinia Therapeutics Inc. is focused on developing gene therapies for various diseases, particularly those affecting the muscles and central nervous system. The company specializes in creating adeno-associated virus (AAV) vectors, leveraging advanced techniques in synthetic and systems biology, as well as high-throughput screening and tissue and single-cell resolution. Founded in 2019 and based in Waltham, Massachusetts, Affinia aims to address significant unmet medical needs by providing rationally designed gene therapies with improved properties. The company's innovative approach seeks to offer effective treatments for devastating conditions that currently lack adequate therapeutic options.

Adagene is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology antibodies targeting novel epitopes for cancer treatment. Utilizing its proprietary Smart Antibody Technology, Adagene aims to enhance the success rates of therapeutic antibodies while significantly accelerating the time to market and lowering development costs. The company is dedicated to the research, development, and production of monoclonal antibody drugs, with a pipeline that emphasizes creating therapeutic candidates characterized by functional epitopes and cross-reactivity across species. By transforming the discovery and development processes in the field of antibody-based cancer immunotherapies, Adagene is positioned to make a substantial impact on cancer treatment.

Immuneel Therapeutics provides pioneering cell and gene therapies for cancer treatment. They develop CAR-T cell therapies from patients' blood cells by genetically modifying healthy immune cells to target malignant cells, giving cancer patients access to revolutionary cell-based immunotherapies.

AviadoBio is focused on developing innovative gene therapies aimed at transforming the lives of individuals affected by neurodegenerative disorders, specifically frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages advanced research from King's College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a comprehensive understanding of brain biology with proprietary gene therapy techniques, AviadoBio seeks to address the challenges of effectively delivering treatments to targeted areas in the brain. This approach aims to enhance the therapeutic potential of gene therapies, offering hope for halting or potentially reversing the progression of these debilitating diseases.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its proprietary Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aiming to restore normal genetic function and address the underlying causes of various diseases. By targeting a broad spectrum of conditions with significant unmet medical needs, Prime Medicine seeks to revolutionize the field of genetic medicine through effective and efficient therapeutic solutions.

Sironax is a clinical-stage biotechnology company based in Beijing, China, founded in 2017. The company focuses on developing innovative products and treatments for age-related degenerative diseases, concentrating on mechanisms such as regulated cell death, neuroprotective pathways, and neuroinflammation. By researching apoptosis and other cell death pathways, Sironax aims to create advanced pharmaceuticals that can improve the lives of patients suffering from these conditions. Their goal is to transform the treatment landscape for age-related degenerative diseases, benefiting millions of patients and their families globally.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, that develops a community-owned platform for genomic and medical research. The company's primary offering, LunaDNA, serves as a knowledge database where individuals can share their health and DNA data to contribute to health research and drive medical discoveries. This platform is designed to benefit both non-profit and for-profit health research projects, facilitating collaboration among pharmaceutical, insurance, and healthcare IT companies. In addition to advancing medical research, LunaPBC allows its members to share in the financial benefits derived from medical breakthroughs, promoting a model of shared community ownership.

Created by co-founders of the $40B DNA sequencing leader Illumina, Luna DNA incentivizes the sharing of health and DNA data for research. LunaDNA rewards people for sharing the data they already own while contributing to medical research and discovery that saves lives. DNA sequencing data has become siloed. As personal DNA sequencing has risen in popularity, the data has become siloed as each company looks to maximize their individual profit from this data. There is currently little incentive for consumers to contribute their DNA and health information to a third party database. There are also multiple privacy, security, and trust issues that limit broad participation. The solution is LunaDNA. LunaDNA is a community owned database that rewards individuals shares in the database and rewards for contributing their health and DNA data. Shares entitle members to a share in the profits from medical research and discoveries. The proceeds flow back to the community like dividends as researchers pay to access the data for discovery.

Structure Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel oral therapeutics for chronic diseases with significant unmet medical needs. Utilizing advanced computational and structure-based technology, the company designs orally available small molecules that aim to overcome the limitations of traditional biologic and peptide drugs. Its lead product candidate, GSBR-1290, is a small molecule agonist targeting the glucagon-like peptide-1 receptor, which is relevant for treating type-2 diabetes and obesity. Additionally, Structure Therapeutics is advancing other oral therapeutics targeting G-protein-coupled receptors for conditions such as pulmonary and cardiovascular diseases, including candidates ANPA-0073 and LTSE-2578. The company combines expertise in drug design and development to create differentiated and effective treatments that can have a profound impact on patient care.

Sana Biotechnology is a biotechnology company based in Seattle, Washington, with additional offices in South San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, the company specializes in developing engineered cells as medicines to treat a variety of diseases. Sana Biotechnology focuses on reprogramming cells in the body and replacing damaged cells and tissues, leveraging recent scientific advancements to create new therapeutic options. The company's research spans multiple therapeutic areas with significant unmet needs, including oncology, diabetes, B-cell-mediated autoimmune disorders, and central nervous system conditions. Its pipeline includes various product candidates aimed at addressing these challenges through innovative cell engineering programs.

Singular Genomics is a life science technology company focused on advancing next generation sequencing (NGS) and multiomics technologies to support researchers and clinicians. The company's core platform, the Singular Sequencing Engine, underpins its product offerings, emphasizing accuracy, speed, flexibility, and scalability. Singular Genomics has developed two primary integrated solutions: the G4 Integrated Solution, which targets the NGS market with a combination of instrument and consumable kits, and the PX Integrated Solution, which integrates single cell analysis, spatial analysis, genomics, and proteomics into a versatile platform. These solutions cater to various market segments, including basic biology, oncology, and immunology, enhancing research capabilities across diverse applications.

Genomics plc is focused on transforming healthcare through advanced genomic analysis. The company employs sophisticated methodologies to analyze large integrated datasets of genomic and phenotypic information, aiming to enhance understanding of human biology. By leveraging genetic inference technology, Genomics plc seeks to identify new drug targets for serious diseases and assess individual disease risk. Their analytical platform enables the exploration of genomic sequence data, providing valuable insights that support pharmaceutical companies in reducing risks associated with drug development. This approach not only aims to improve healthcare outcomes but also sets a standard for how organizations and patients can benefit from genomic data.

Avidity Biosciences, Inc. is a biotechnology company focused on developing oligonucleotide-based therapies known as antibody oligonucleotide conjugates (AOCs). These innovative therapies aim to address the limitations of traditional oligonucleotide treatments by combining the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies. This approach allows Avidity to target previously undruggable tissue and cell types, thereby addressing the underlying genetic drivers of various diseases. The company's lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, a rare muscle disease. Additionally, Avidity is advancing multiple programs aimed at treating muscle-related conditions such as muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. Founded in 2012 and based in La Jolla, California, Avidity is also exploring therapeutic applications in immune and other cell types.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Benchling, Inc. is a developer of a cloud-based informatics platform tailored for life sciences research and development. The platform includes a suite of integrated applications that allow scientists to design, share, and document experiments, as well as manage biological entities like plasmids and antibodies. Key features include Benchling Insights, which enables users to visualize and collaborate on structured data, and a biological registration system for inventory tracking. Benchling's solutions cater to a diverse range of applications such as gene therapy, vaccines, and industrial biotechnology, serving scientists in biotech, pharmaceutical, academic, and government sectors. Established in 2012 and based in San Francisco, the company aims to enhance the speed and collaboration of life science research by providing tools that streamline workflows and facilitate critical R&D decisions.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Biopalette is a company focused on developing advanced gene-editing techniques aimed at creating innovative therapies. The business operates a platform that combines genome editing and microbiome engineering, allowing for the cultivation of bacteria through targeted genome modifications. This technology enables scientists to explore and test various applications in gene editing, specifically tailored to different types of cells. Biopalette's approach positions it at the intersection of genetics and microbiome science, facilitating breakthroughs in therapeutic development.

Orchard Therapeutics is a biopharmaceutical company based in the United Kingdom that specializes in developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which modifies a patient's own hematopoietic stem cells to create a targeted treatment administered in a single dose. Orchard's portfolio includes Strimvelis, the first autologous gene therapy approved by the European Medicines Agency for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Additionally, it is advancing clinical programs for various conditions, including metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has an extensive preclinical pipeline targeting mucopolysaccharidosis types I, IIIA, and IIIB. Orchard Therapeutics collaborates with leading institutions in gene therapy research, enhancing its efforts to transform the lives of patients with rare diseases in the UK, European Union, and the United States. Founded in 2015 and headquartered in London, it aims to provide sustainable clinical benefits through its innovative therapies.

Indalo Therapeutics is a preclinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating fibrotic diseases. Founded on groundbreaking scientific discoveries and leveraging cutting-edge insight into the molecular drivers of aberrant scarring, Indalo is harnessing the collective experience of a seasoned team of pharmaceutical scientists and executives to tackle some of the most urgent unmet medical needs in the fibrosis space.

Biopalette is a company focused on developing advanced gene-editing techniques aimed at creating innovative therapies. The business operates a platform that combines genome editing and microbiome engineering, allowing for the cultivation of bacteria through targeted genome modifications. This technology enables scientists to explore and test various applications in gene editing, specifically tailored to different types of cells. Biopalette's approach positions it at the intersection of genetics and microbiome science, facilitating breakthroughs in therapeutic development.

Biopalette is a company focused on developing advanced gene-editing techniques aimed at creating innovative therapies. The business operates a platform that combines genome editing and microbiome engineering, allowing for the cultivation of bacteria through targeted genome modifications. This technology enables scientists to explore and test various applications in gene editing, specifically tailored to different types of cells. Biopalette's approach positions it at the intersection of genetics and microbiome science, facilitating breakthroughs in therapeutic development.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who typically rely on insulin injections. The company was founded based on groundbreaking research by Professor Douglas Melton, which enabled the generation of functional, insulin-producing beta cells in the laboratory. This technology has been exclusively licensed to Semma Therapeutics, and the company aims to combine these proprietary cells with advanced devices to create a functional replacement for the missing beta cells without the need for immunosuppression. Headquartered in Cambridge, Massachusetts, with an additional office in Boston, Semma Therapeutics operates as a subsidiary of Vertex Pharmaceuticals and is dedicated to advancing this new therapeutic option to improve the lives of diabetes patients.

Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.

Cytek Biosciences, Inc. is a manufacturer and supplier of flow cytometry tools and equipment, primarily serving cancer and cell biology research. The company offers a range of products including the Cytek Aurora and Cytek Northern Lights flow cytometers, the DxP Athena flow cytometry system that utilizes advanced technology to resolve dim populations in a multicolor format, and the QbSure quality control program for assessing cytometer performance. Additionally, Cytek provides proprietary cFluor reagents designed to optimize instrument performance in multicolor applications. Established in 1990 and headquartered in Fremont, California, Cytek has expanded its presence with locations in Bethesda, Maryland; Amsterdam, the Netherlands; Tokyo, Japan; and Shanghai, China. The company, formerly known as Cytoville, Inc., rebranded to Cytek Biosciences, Inc. in August 2015.

Core Diagnostics is a Clinical laboratory focused on Next Generation Diagnostics for disease stratification and therapy selection. We are focused on bringing the most advanced testing techniques and expertise to India. We aim to become the destination for all your high-end diagnostic needs.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Caribou Biosciences, Inc. is a biotechnology company focused on cellular engineering and genome editing using CRISPR technology. Established in 2011 and based in Berkeley, California, the company leverages its CRISPR-Cas gene editing platform to facilitate precise modifications in DNA across various applications. These include developing therapeutics for human and animal health, creating disease models, enhancing agricultural traits, and advancing industrial biotechnology. Caribou Biosciences is particularly dedicated to the development of genome-edited cell therapies, including allogeneic CAR-T and CAR-NK cell therapies, aimed at improving outcomes for patients with severe diseases. The company’s innovative approach combines CRISPR with guide RNA to enable targeted DNA alterations, thereby contributing to advancements in both therapeutic development and biological research.

Orchard Therapeutics is a biopharmaceutical company based in the United Kingdom that specializes in developing innovative gene therapies for serious and life-threatening rare diseases. The company employs an autologous ex vivo gene therapy approach, which modifies a patient's own hematopoietic stem cells to create a targeted treatment administered in a single dose. Orchard's portfolio includes Strimvelis, the first autologous gene therapy approved by the European Medicines Agency for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Additionally, it is advancing clinical programs for various conditions, including metachromatic leukodystrophy, Wiskott-Aldrich syndrome, X-linked chronic granulomatous disease, and transfusion-dependent beta-thalassemia. The company also has an extensive preclinical pipeline targeting mucopolysaccharidosis types I, IIIA, and IIIB. Orchard Therapeutics collaborates with leading institutions in gene therapy research, enhancing its efforts to transform the lives of patients with rare diseases in the UK, European Union, and the United States. Founded in 2015 and headquartered in London, it aims to provide sustainable clinical benefits through its innovative therapies.

Adagene is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology antibodies targeting novel epitopes for cancer treatment. Utilizing its proprietary Smart Antibody Technology, Adagene aims to enhance the success rates of therapeutic antibodies while significantly accelerating the time to market and lowering development costs. The company is dedicated to the research, development, and production of monoclonal antibody drugs, with a pipeline that emphasizes creating therapeutic candidates characterized by functional epitopes and cross-reactivity across species. By transforming the discovery and development processes in the field of antibody-based cancer immunotherapies, Adagene is positioned to make a substantial impact on cancer treatment.

Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, utilizing proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body’s immune system in the fight against cancer. The company designs targeted treatments aimed at addressing the underlying causes of diseases, thereby improving patient outcomes. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor that specifically targets the KIT D816V mutation and other mutations in KIT exon 17. This mutation is predominantly linked to Systemic Mastocytosis, a severe condition resulting from the uncontrolled growth of mast cells, and is also associated with advanced gastrointestinal stromal tumors. Cogent Biosciences is advancing its lead program, which is expected to enter Phase I clinical trials to evaluate safety and efficacy.

REGENXBIO Inc. is a clinical-stage biotechnology company specializing in gene therapy aimed at addressing genetic defects and enabling cells to produce therapeutic proteins and antibodies. The company utilizes its proprietary NAV Technology Platform, which involves recombinant adeno-associated virus vectors for gene delivery. REGENXBIO’s lead candidate, RGX-314, is currently in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. Additional product candidates under development include RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I, RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia. Beyond its own product candidates, REGENXBIO also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and has a collaboration agreement with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.

Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for women's health infections, particularly bacterial vaginosis (BV). Founded in 2012 and headquartered in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut, the company specializes in the development of its lead product, Solosec (secnidazole), a next-generation 5-nitroimidazole antibiotic designed for a convenient one-dose treatment. This drug offers enhanced pharmacokinetic properties that improve efficacy and tolerability for patients. Symbiomix is supported by prominent healthcare venture capital firms and aims to address the unmet therapeutic needs in the field of gynecologic infections. Since October 2017, it has operated as a subsidiary of Lupin Inc.

Caribou Biosciences, Inc. is a biotechnology company focused on cellular engineering and genome editing using CRISPR technology. Established in 2011 and based in Berkeley, California, the company leverages its CRISPR-Cas gene editing platform to facilitate precise modifications in DNA across various applications. These include developing therapeutics for human and animal health, creating disease models, enhancing agricultural traits, and advancing industrial biotechnology. Caribou Biosciences is particularly dedicated to the development of genome-edited cell therapies, including allogeneic CAR-T and CAR-NK cell therapies, aimed at improving outcomes for patients with severe diseases. The company’s innovative approach combines CRISPR with guide RNA to enable targeted DNA alterations, thereby contributing to advancements in both therapeutic development and biological research.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who typically rely on insulin injections. The company was founded based on groundbreaking research by Professor Douglas Melton, which enabled the generation of functional, insulin-producing beta cells in the laboratory. This technology has been exclusively licensed to Semma Therapeutics, and the company aims to combine these proprietary cells with advanced devices to create a functional replacement for the missing beta cells without the need for immunosuppression. Headquartered in Cambridge, Massachusetts, with an additional office in Boston, Semma Therapeutics operates as a subsidiary of Vertex Pharmaceuticals and is dedicated to advancing this new therapeutic option to improve the lives of diabetes patients.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

TraceLink, Inc. is a company that specializes in track and trace network solutions for the life sciences supply chain, focusing on the prevention of counterfeit prescription drugs. Founded in 2009 and headquartered in North Reading, Massachusetts, TraceLink offers a range of products, including pharmaceutical serialization, drug tracking compliance, and supply network performance solutions. Its notable offerings include the TraceLink Life Sciences Cloud, Smart Rx Manager, and Serialized Product Intelligence, which collectively support compliance with regulations such as the European Union Falsified Medicines Directive. TraceLink serves a diverse clientele, including pharmaceutical companies, wholesale distributors, and re-packagers. The company has established strategic partnerships with various organizations to enhance its service offerings. With additional offices in the United Kingdom, India, Singapore, and Brazil, TraceLink operates as a global entity, dedicated to creating integrated business ecosystems that promote agility and resiliency in supply networks.

Innovent Biologics, Inc. is a leading biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacture, and commercialization of monoclonal antibodies. The company focuses on various therapeutic areas, including oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody used in the treatment of several cancers, including Hodgkin’s lymphoma and esophageal carcinoma. Innovent is also developing a range of additional drug candidates, such as biosimilars for rituximab and adalimumab, as well as novel monoclonal antibodies targeting conditions like hypercholesterolemia and different types of cancer. With a robust pipeline and over 30 strategic collaborations with global pharmaceutical companies, Innovent is well-positioned in the biopharmaceutical landscape. The company's founders and management team bring extensive experience in biologics, having participated in the launch of notable products across international markets. Innovent was founded in 2011 and has established itself as a prominent player in the biotechnology sector in China.

REGENXBIO Inc. is a clinical-stage biotechnology company specializing in gene therapy aimed at addressing genetic defects and enabling cells to produce therapeutic proteins and antibodies. The company utilizes its proprietary NAV Technology Platform, which involves recombinant adeno-associated virus vectors for gene delivery. REGENXBIO’s lead candidate, RGX-314, is currently in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. Additional product candidates under development include RGX-121 for mucopolysaccharidosis type II, RGX-111 for mucopolysaccharidosis type I, RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia. Beyond its own product candidates, REGENXBIO also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and has a collaboration agreement with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.

Cytek Biosciences, Inc. is a manufacturer and supplier of flow cytometry tools and equipment, primarily serving cancer and cell biology research. The company offers a range of products including the Cytek Aurora and Cytek Northern Lights flow cytometers, the DxP Athena flow cytometry system that utilizes advanced technology to resolve dim populations in a multicolor format, and the QbSure quality control program for assessing cytometer performance. Additionally, Cytek provides proprietary cFluor reagents designed to optimize instrument performance in multicolor applications. Established in 1990 and headquartered in Fremont, California, Cytek has expanded its presence with locations in Bethesda, Maryland; Amsterdam, the Netherlands; Tokyo, Japan; and Shanghai, China. The company, formerly known as Cytoville, Inc., rebranded to Cytek Biosciences, Inc. in August 2015.

Adagene is a clinical-stage biopharmaceutical company focused on developing innovative immuno-oncology antibodies targeting novel epitopes for cancer treatment. Utilizing its proprietary Smart Antibody Technology, Adagene aims to enhance the success rates of therapeutic antibodies while significantly accelerating the time to market and lowering development costs. The company is dedicated to the research, development, and production of monoclonal antibody drugs, with a pipeline that emphasizes creating therapeutic candidates characterized by functional epitopes and cross-reactivity across species. By transforming the discovery and development processes in the field of antibody-based cancer immunotherapies, Adagene is positioned to make a substantial impact on cancer treatment.

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, utilizing proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body’s immune system in the fight against cancer. The company designs targeted treatments aimed at addressing the underlying causes of diseases, thereby improving patient outcomes. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor that specifically targets the KIT D816V mutation and other mutations in KIT exon 17. This mutation is predominantly linked to Systemic Mastocytosis, a severe condition resulting from the uncontrolled growth of mast cells, and is also associated with advanced gastrointestinal stromal tumors. Cogent Biosciences is advancing its lead program, which is expected to enter Phase I clinical trials to evaluate safety and efficacy.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

Blueprint Medicines is a biopharmaceutical company dedicated to developing targeted therapies for cancers and rare diseases driven by abnormal kinase activation. Founded in 2008 and based in Cambridge, Massachusetts, the company utilizes its proprietary Insights-to-Validation Platform and chemical library to create small molecule kinase inhibitors that address specific genomic drivers. Key drug candidates include avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, BLU-263 for indolent systemic mastocytosis, and pralsetinib for RET-altered cancers such as non-small cell lung cancer and medullary thyroid carcinoma. Additionally, fisogatinib is under investigation for advanced hepatocellular carcinoma, while BLU-782 targets fibrodysplasia ossificans progressiva. Blueprint Medicines collaborates with several pharmaceutical companies to enhance its research and development efforts.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who typically rely on insulin injections. The company was founded based on groundbreaking research by Professor Douglas Melton, which enabled the generation of functional, insulin-producing beta cells in the laboratory. This technology has been exclusively licensed to Semma Therapeutics, and the company aims to combine these proprietary cells with advanced devices to create a functional replacement for the missing beta cells without the need for immunosuppression. Headquartered in Cambridge, Massachusetts, with an additional office in Boston, Semma Therapeutics operates as a subsidiary of Vertex Pharmaceuticals and is dedicated to advancing this new therapeutic option to improve the lives of diabetes patients.

Symbiomix Therapeutics, LLC is a biopharmaceutical company focused on developing innovative treatments for women's health infections, particularly bacterial vaginosis (BV). Founded in 2012 and headquartered in Newark, New Jersey, with additional offices in Baltimore, Maryland, and Hamden, Connecticut, the company specializes in the development of its lead product, Solosec (secnidazole), a next-generation 5-nitroimidazole antibiotic designed for a convenient one-dose treatment. This drug offers enhanced pharmacokinetic properties that improve efficacy and tolerability for patients. Symbiomix is supported by prominent healthcare venture capital firms and aims to address the unmet therapeutic needs in the field of gynecologic infections. Since October 2017, it has operated as a subsidiary of Lupin Inc.

Innovent Biologics, Inc. is a leading biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacture, and commercialization of monoclonal antibodies. The company focuses on various therapeutic areas, including oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody used in the treatment of several cancers, including Hodgkin’s lymphoma and esophageal carcinoma. Innovent is also developing a range of additional drug candidates, such as biosimilars for rituximab and adalimumab, as well as novel monoclonal antibodies targeting conditions like hypercholesterolemia and different types of cancer. With a robust pipeline and over 30 strategic collaborations with global pharmaceutical companies, Innovent is well-positioned in the biopharmaceutical landscape. The company's founders and management team bring extensive experience in biologics, having participated in the launch of notable products across international markets. Innovent was founded in 2011 and has established itself as a prominent player in the biotechnology sector in China.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.

LakeShore Biopharma is a global, fully integrated medical company engaged in discovering, developing and commercializing innovative biotherapeutics for cancers and infectious diseases using our novel PIKA® immunomodulating technology. PIKA technology augments both innate and adaptive immune responses through the TLR3, RIG-I and MDA5 pathways. Products in clinical development include YS-ON-001 for the treatment of advanced solid tumors, YS-HBV-001 hepatitis B vaccine and the PIKA rabies vaccine for accelerated protection against rabies infection.

Innovent Biologics, Inc. is a leading biopharmaceutical company based in Suzhou, China, specializing in the discovery, development, manufacture, and commercialization of monoclonal antibodies. The company focuses on various therapeutic areas, including oncology, ophthalmology, immunology, and metabolic diseases. Its flagship product, Tyvyt (sintilimab), is an anti-PD-1 monoclonal antibody used in the treatment of several cancers, including Hodgkin’s lymphoma and esophageal carcinoma. Innovent is also developing a range of additional drug candidates, such as biosimilars for rituximab and adalimumab, as well as novel monoclonal antibodies targeting conditions like hypercholesterolemia and different types of cancer. With a robust pipeline and over 30 strategic collaborations with global pharmaceutical companies, Innovent is well-positioned in the biopharmaceutical landscape. The company's founders and management team bring extensive experience in biologics, having participated in the launch of notable products across international markets. Innovent was founded in 2011 and has established itself as a prominent player in the biotechnology sector in China.

Blueprint Medicines is a biopharmaceutical company dedicated to developing targeted therapies for cancers and rare diseases driven by abnormal kinase activation. Founded in 2008 and based in Cambridge, Massachusetts, the company utilizes its proprietary Insights-to-Validation Platform and chemical library to create small molecule kinase inhibitors that address specific genomic drivers. Key drug candidates include avapritinib for systemic mastocytosis and gastrointestinal stromal tumors, BLU-263 for indolent systemic mastocytosis, and pralsetinib for RET-altered cancers such as non-small cell lung cancer and medullary thyroid carcinoma. Additionally, fisogatinib is under investigation for advanced hepatocellular carcinoma, while BLU-782 targets fibrodysplasia ossificans progressiva. Blueprint Medicines collaborates with several pharmaceutical companies to enhance its research and development efforts.

Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.

BIKAM Pharmaceuticals is a drug discovery company based in Cambridge, Massachusetts, established in 2007. The company specializes in developing novel therapeutics aimed at treating retinal degenerative diseases, particularly focusing on conditions such as retinitis pigmentosa and dry age-related macular degeneration. BIKAM's research centers on small molecule, non-retinoid pharmacological chaperones designed to address issues related to misfolded proteins within the retina. Their lead product is an orally active pharmacological chaperone that targets misfolded rod opsin, which is implicated in retinitis pigmentosa, helping to correct its trafficking to the rod cell surface and outer segment. Through its innovative approach, BIKAM Pharmaceuticals strives to provide new treatment options for patients suffering from these serious retinal conditions.

Mersana Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of antibody-drug conjugates (ADCs) for cancer treatment. The company utilizes its proprietary biodegradable polymer platform, Dolaflexin, to create a pipeline of ADC product candidates aimed at addressing oncology indications with significant unmet needs. Its lead candidate, XMT-1536, is currently in Phase I clinical trials targeting NaPi2b for the treatment of ovarian cancer, non-small cell lung cancer, and other rare conditions. Mersana is also advancing additional candidates, including XMT-1660, targeting B7-H4, and XMT-2056, a STING agonist ADC, both designed to improve tolerability and therapeutic outcomes. The company has established strategic partnerships with Merck KGaA and Asana BioSciences to further develop its ADC candidates. Founded in 2005, Mersana Therapeutics aims to deliver innovative treatments to patients through its advanced research and development efforts.